undamentalytics Newsletter
Sign in

Sinovac Biotech LTD cash flow statement

In fiscal 2025, Sinovac Biotech LTD's operations generated −$512m of cash; it spent $48.9m on capital projects, leaving free cash flow of −$561m. It returned $3.53bn in dividends.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations0.0−0.00.0−0.00.10.00.00.515.3−0.80.1−0.1−0.5
Depreciation and amortisation0.00.00.00.00.00.00.00.00.10.20.20.10.1
Stock-based pay0.00.00.00.00.00.00.00.00.00.00.00.00.0
Capital spending0.00.00.00.00.00.00.00.10.60.30.20.10.0
Free cash flow0.0−0.0−0.0−0.00.00.00.00.414.7−1.1−0.0−0.2−0.6
Free cash flow after stock pay0.0−0.0−0.0−0.00.0−0.00.00.314.7−1.1−0.0−0.2−0.6
Dividends paid0.00.00.0———0.00.01.90.20.30.93.5
Share buybacks0.0————————————
Shares issued0.00.10.00.00.00.10.00.00.00.00.00.00.0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MNKD vs SVAPHAR vs SVAMGTX vs SVANVAX vs SVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sinovac Biotech LTD's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Sinovac Biotech LTD.